| Iupac name | 2-(2-(4-((1Z)-4-Chloro-1,2-diphenylbut-1-enyl)phenoxy)ethoxy)ethanol |
|---|---|
| Width | 250 |
| Cas number | 341524-89-8 |
| Pubchem | 9954033 |
| Chemspiderid | 8129643 |
| Unii | 3VZ2833V08 |
| Kegg | D10008 |
| Chembl | 2107341 |
| C | 26 |
| H | 27 |
| Cl | 1 |
| O | 3 |
| Smiles | C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCOCCO)/CCCl |
| Stdinchi | 1S/C26H27ClO3/c27-16-15-25(21-7-3-1-4-8-21)26(22-9-5-2-6-10-22)23-11-13-24(14-12-23)30-20-19-29-18-17-28/h1-14,28H,15-20H2/b26-25- |
| Stdinchikey | NKZTZAQIKKGTDB-QPLCGJKRSA-N |
| Synonyms | HM-101 |
Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed.[1][2][3] It reached phase II clinical trials for this indication before development was terminated in March 2016.[1] The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.[1]
See also
References
- ^ "Fispemifene". AdisInsight. Springer Nature Switzerland AG.
- ^ Cano A, Calaf i Alsina J, Duenas-Diez JL (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 52–. ISBN 978-3-540-34742-2.
- ^ Ottow E, Weinmann H (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 90–. ISBN 978-3-527-62330-3.